SCHEMBL1979241

SCHEMBL1979241

O=C(O)c1ccc(OCCCN2C[C@H]3CC[C@H]3C2)cc1

nearest known ligand 0.70

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 4/20 0.70
MAOB P27338 1/20 0.53
HRH2 P25021 1/20 0.53
HRH1 P35367 1/20 0.53
KDM1A O60341 2/20 0.53
PKM P14618 1/20 0.51
TBXAS1 P24557 1/20 0.51
KDM4E B2RXH2 4/20 0.50
MAPK1 P28482 1/20 0.50
TP53 P04637 1/20 0.50
TSHR P16473 1/20 0.50
ALDH1A1 P00352 3/20 0.49
MEN1 O00255 1/20 0.49
HTT P42858 1/20 0.49
KMT2A Q03164 1/20 0.49
PLA2G4B P0C869 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14163721 0.94 HRH3 (0.79) HRH3MAOBHRH2HRH1KDM1A
SCHEMBL3826442 0.91 HRH3 (0.62) HRH3MAOBHRH2HRH1KDM1A
SCHEMBL1977578 0.87 HRH3 (0.90) HRH3MAOBHRH2HRH1TBXAS1
Oxalic Acid SCHEMBL1976615 0.87 HRH3 (0.83) HRH3MAOBHRH2HRH1KDM4E
Hydrochloric Acid SCHEMBL1979057 0.86 HRH3 (0.88) HRH3MAOBHRH2HRH1TBXAS1
Hydrochloric Acid SCHEMBL1979659 0.86 HRH3 (0.67) HRH3MAOBHRH2HRH1KDM4E
SCHEMBL1978634 0.85 HRH3 (0.65) HRH3MAOBHRH2HRH1KDM4E
SCHEMBL2025211 0.84 HRH3 (0.64) HRH3MAOBHRH2HRH1TBXAS1
SCHEMBL1978514 0.84 HRH3 (0.64) HRH3MAOBHRH2HRH1TBXAS1
SCHEMBL1979219 0.83 HRH3 (0.83) HRH3MAOBHRH2HRH1TBXAS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2332910-B1 New derivatives of azabicyclo[3.2.0]hept-3-yl, method for preparing same and pharmaceutical compositions containing them SERVIER LAB (FR) 2013-01-30 EP disclosed
US-8008337-B2 Azabicyclo[3.2.0] hept-3-yl compounds, a process for their preparation and pharmaceutical compositions containing them LES LABORATOIRES SERVIER (FR) 2011-08-30 US disclosed
EP-2332910-A1 New derivatives of azabicyclo[3.2.0]hept-3-yl, method for preparing same and pharmaceutical compositions containing them Les Laboratoires Servier (FR) 2011-06-15 EP disclosed
US-20110136886-A1 Azabicyclo[3.2.0] hept-3-yl compounds, a process for their preparation and pharmaceutical compositions containing them LES LABORATOIRES SERVIER (FR) 2011-06-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110136886-A1 Azabicyclo[3.2.0] hept-3-yl compounds, a process for their preparation and pharmaceutical compositions containing them HRH2, HRH4, HRH3 HRH3 3/4885MAOB 78/4885HRH2 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.